Basic Femara Information

• INN (International Nonproprietary Name): Letrozole
• Brand Names Available In United Kingdom: Femara — 2.5 mg tablets, 14 or 30 per pack
• ATC Code: L02BG04 — Aromatase Inhibitors
• Forms & Dosages: Oral film-coated tablets, 2.5 mg; typical pack sizes include 7, 10, 14, 28, 30 or 100 tablets; no injectable or topical forms available
• Manufacturers In United Kingdom: Originator Novartis Pharma AG; licensed generics supplied in the UK market (for example, Sandoz)
• Registration Status In United Kingdom: Not specified
• OTC / Rx Classification: Prescription Only (Rx). Letrozole/Femara is never available over-the-counter in any jurisdiction.

Latest Research Highlights (UK And EU Studies, 2022–2025)

Worried about whether recent evidence changes how Femara is used in the UK?

Recent UK and EU studies from 2022 to 2025 continue to support letrozole as a standard aromatase inhibitor for postmenopausal, hormone-receptor-positive breast cancer.

Randomised trials and pooled meta-analyses reported comparable or superior disease-free survival for letrozole 2.5 mg once daily versus tamoxifen in appropriate postmenopausal populations.

Large NHS registry analyses through 2024 reflect trial outcomes in routine practice, showing similar recurrence reductions outside trial settings.

Key contemporary themes include benefit from extended adjuvant therapy in selected patients and consistent first-line efficacy in advanced or metastatic disease.

Safety monitoring is emphasised, with musculoskeletal pain, hot flushes, fatigue and modest bone mineral density decline reported frequently in EU pharmacovigilance summaries.

Several recent papers explore bone-loss mitigation strategies such as bisphosphonates or denosumab and propose lipid and cardiovascular monitoring pathways suitable for NHS practice.

Below is a concise comparison of trial outcomes versus NHS registry findings to aid clinicians.

Clinical Effectiveness In The UK (NHS Outcomes And Patient-Reported Data)

Want to know what patients actually experience on Femara within the NHS?

Letrozole (Femara 2.5 mg once daily) is prescribed per MHRA licensing for postmenopausal, hormone-receptor-positive breast cancer in adjuvant, extended adjuvant and metastatic settings.

UK audits and patient-reported outcome studies show sustained reductions in recurrence when letrozole is used according to guidance and when adherence is maintained.

Patient-reported data collected via NHS services and charities such as Macmillan frequently list arthralgia, fatigue and vasomotor symptoms as main reasons for reduced adherence.

Clinicians increasingly perform baseline DXA scanning and periodic bone density monitoring when initiating aromatase inhibitors.

NICE and local trust guidance inform duration choices and switching strategies, for example starting an aromatase inhibitor after a course of tamoxifen.

Community pharmacists in Boots, LloydsPharmacy and Superdrug play a key role in adherence counselling and side-effect management, using NHS electronic prescribing and patient portals.

• NHS Outcome Measures: Recurrence, overall survival, adherence rate, DXA monitoring uptake.

Indications And Expanded Uses (MHRA-Approved Versus Off-Label)

Confused about when Femara is approved and when it is used off-label?

MHRA and EMA approvals limit letrozole to postmenopausal women with hormone-receptor-positive breast cancer for adjuvant therapy, first-line advanced disease and extended adjuvant schedules.

The standard adult dose is 2.5 mg once daily taken orally with or without food.

Extended adjuvant therapy may extend overall aromatase inhibitor exposure up to five years in selected patients, sometimes within a broader 10-year strategy that includes tamoxifen exposure.

Off-label use is most commonly seen in fertility clinics for ovulation induction, but this application is not an authorised indication in the UK and should occur only under specialist supervision.

Letrozole is contraindicated in premenopausal women and in pregnancy or lactation.

1. Approved Indications: Adjuvant early breast cancer; first-line advanced/metastatic disease; extended adjuvant therapy in postmenopausal HR+ patients.
2. Off-Label Uses: Ovulation induction in fertility clinics — specialist oversight required.

Clinician decision checklists commonly include confirmation of postmenopausal status, documented hormone-receptor positivity and baseline bone health assessment.

Composition And Brand Landscape (Active Ingredient, UK Brands, Generics)

Want to know what you are actually taking when the label says Femara?

The active ingredient is letrozole, a non-steroidal aromatase inhibitor sold as the originator brand Femara and in multiple generics in the UK market.

Femara is supplied in 2.5 mg film-coated tablets with common pack sizes of 14 or 30 tablets for UK dispensing.

Novartis Pharma AG is the originator manufacturer and licensed generics are supplied by companies such as Sandoz; other international producers manufacture generics for non-UK markets.

The ATC code is L02BG04, placing letrozole among aromatase inhibitors used in oncology.

All authorised forms are oral tablets; there are no alternative formulations such as injectables or creams.

Pharmacy supply in the UK is prescription-only and NHS prescribing commonly favours generics for cost reasons, although clinicians may note brand preferences where relevant.

Contraindications And Special Precautions (High-Risk Groups And Lifestyle Restrictions)

Worried about whether Femara is safe for you or someone you care for?

Absolute contraindications include premenopausal status, pregnancy, breastfeeding and known hypersensitivity to letrozole or tablet excipients.

Relative cautions listed in regulatory data include severe hepatic or renal impairment, pre-existing osteoporosis or significant osteopenia, history of ischaemic heart disease and concurrent use of potent CYP450 modulators.

Clinical practice in the UK emphasises baseline DXA scanning for patients with risk factors and routine lipid and cardiovascular risk assessment when starting therapy.

Lifestyle advice commonly given includes effective contraception during treatment, moderation of alcohol intake due to bone and cardiovascular considerations, and caution with high-impact sports if significant arthralgia or osteoporosis is present.

There is no routine driving restriction, but counsel patients to avoid driving if they experience dizziness or severe fatigue.

MHRA Yellow Card reporting highlights musculoskeletal pain and bone density loss as prominent adverse events and patients should be encouraged to report serious events promptly.

Dosage Guidelines (NHS-Recommended Regimens And Adjustments)

Want clear, practical dosing and what to do if a dose is missed?

The standard adult dose is 2.5 mg once daily taken orally with or without food, commonly supplied in 14 or 30 tablet blister packs.

Adjuvant therapy is often given for five years, with selected patients offered extended adjuvant aromatase inhibitor therapy to reach a total aromatase inhibitor exposure of up to five additional years following tamoxifen.

For elderly patients no routine dose reduction is necessary and mild to moderate hepatic or renal impairment usually requires no adjustment.

There are no established paediatric doses and letrozole is not indicated in children.

Missed-dose advice: take as soon as remembered unless it is near the next scheduled dose; never double the dose.

Overdose management is supportive; there is no specific antidote.

Interactions Overview (Drugs, Food, MHRA Yellow Card Reports)

Worried that another medication or food will affect Femara?

Letrozole has no major food interactions and may be taken with or without food.

Alcohol should be used in moderation because of additive effects on bone and cardiovascular risk with long-term aromatase inhibitor therapy.

Letrozole is metabolised via CYP450 pathways, so potent CYP3A4 inhibitors or inducers may alter plasma levels and co-prescribing should be managed case-by-case.

Oestrogen-containing medicines, including HRT and combined hormonal contraceptives, are contraindicated because they can counteract letrozole's mechanism of action.

MHRA Yellow Card submissions have recorded interaction-related tolerability issues in some patients, for example concurrent statin therapy associated with myalgia when combined with aromatase inhibitor therapy.

Cultural Perceptions And Patient Habits (UK Forums, Trust In Pharmacists)

Curious what people say online about taking Femara in the UK?

Patients commonly share experiences on NHS forums, Patient.info, Mumsnet and Reddit describing menopausal-style side effects and concern over long-term bone health.

Many UK patients report turning first to their oncology team for detailed counselling and then to community pharmacists for practical day-to-day advice and repeat prescriptions.

Pharmacist counselling at high-street chains such as Boots and LloydsPharmacy is frequently cited positively for medication management and side-effect mitigation.

Electronic prescriptions and NHS patient portals have improved access to repeat supplies and symptom reporting, but patients still describe regional variation in face-to-face counselling across England, Scotland, Wales and Northern Ireland.

• Common Patient Perceptions: Expectation of hot flushes, joint pain and an interest in bone protection options.

Case vignette: A patient phoned her local pharmacy with worsening joint pain and the pharmacist arranged a medication review, advised reporting to the oncology team and requested a DXA referral — the quick intervention improved adherence and symptoms management.

Availability And Pricing Patterns (Boots, Lloyds, NHS Prices, Regional Variations)

Wondering how to get Femara in the UK and what it will cost?

Letrozole/Femara is prescription-only in the UK and NHS prescriptions usually favour generics for cost effectiveness.

Pack sizes commonly dispensed are 14 or 30 tablets of 2.5 mg strength, and private prescriptions or online pharmacies may offer home delivery.

Prescription charges differ by nation; England retains the standard prescription charge for most patients, while Scotland, Wales and Northern Ireland have abolished patient prescription charges.

Private costs depend on whether the originator brand Femara or a generic is supplied, plus any pharmacy dispensing fee on private scripts.

Supply chains are generally stable but occasional shortages of specific branded packs occur; community pharmacists will substitute generics within clinical guidance if required.

In our online pharmacy, femara is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

For repeat prescriptions use NHS e-prescription services or local pharmacy repeat dispensing where available to reduce delays.

Comparable Medicines And Prescribing Preferences (Anastrozole, Exemestane, Tamoxifen)

Trying to decide whether Femara is the right aromatase inhibitor compared with others?

Comparable aromatase inhibitors include anastrozole and exemestane, while tamoxifen remains an alternative, particularly for premenopausal patients or where aromatase inhibitors are contraindicated.

Trust and clinician preference, side-effect profiles, cost and patient comorbidities such as baseline osteoporosis influence choice among aromatase inhibitors in NHS formularies.

Letrozole is non-steroidal and used widely for its efficacy profile; exemestane is a steroidal inactivator sometimes used for sequencing strategies after non-steroidal agents.

Anastrozole offers a similar efficacy profile and is often selected according to local formulary or cost considerations.

FAQ Section

1. Will letrozole cause menopause-like symptoms?

Many patients experience hot flushes, joint pain and fatigue; severity varies and NHS clinicians can offer symptomatic treatments and support strategies.

2. How will my bone health be managed?

Baseline DXA scanning is standard for at-risk patients and bisphosphonates or denosumab may be recommended for prevention or treatment following NICE guidance.

3. Can I take HRT or contraceptive pills?

Oestrogen-containing medicines counteract letrozole and are not recommended; discuss non-hormonal contraception or specialist alternatives with your oncology team.

4. Is letrozole safe if I wish to get pregnant later?

Letrozole is teratogenic and effective contraception is mandatory during treatment; specialist advice is required on timing pregnancy after stopping therapy.

For further patient leaflets consult NHS oncology pages and report serious adverse events via the MHRA Yellow Card scheme.

Guidelines For Proper Use (Pharmacist Counselling And NHS Portals)

Need a practical checklist for counselling patients starting Femara?

Verify menopausal status and the documented indication for letrozole before counselling or dispensing.

Confirm the prescription-only status and advise dosing as 2.5 mg once daily with missed-dose rules explained.

Discuss common side effects such as arthralgia, hot flushes and fatigue and provide management strategies or referrals as needed.

Advise baseline DXA scheduling where risk factors exist and recommend lipid checks and cardiovascular risk assessment during follow-up.

Warn patients to avoid oestrogen-containing preparations and to use effective contraception during treatment.

Use NHS e-prescription and patient portals to arrange medication reviews and remote symptom reporting and liaise promptly with oncology teams for intolerance or interaction concerns.

• Pharmacy Counselling Checklist: Confirm indication and menopausal status; explain dosing; review bone and CV risks; arrange DXA if indicated; provide Yellow Card reporting information.

Provide patients with a short handout summarising dose, common side effects, contact numbers for oncology and instructions for missed doses.

Delivery Across United Kingdom